Natus Medical Inc. (BABY) Position Increased by Systematic Financial Management LP
Systematic Financial Management LP increased its position in shares of Natus Medical Inc. (NASDAQ:BABY) by 10.4% during the second quarter, Holdings Channel reports. The fund owned 50,374 shares of the company’s stock after buying an additional 4,740 shares during the period. Systematic Financial Management LP owned approximately 0.16% of Natus Medical worth $1,904,000 at the end of the most recent quarter.
Several other hedge funds also recently added to or reduced their stakes in BABY. Suntrust Banks Inc. increased its stake in Natus Medical by 3.7% in the second quarter. Suntrust Banks Inc. now owns 5,776 shares of the company’s stock worth $218,000 after buying an additional 204 shares during the last quarter. Arizona State Retirement System increased its stake in Natus Medical by 2.4% in the first quarter. Arizona State Retirement System now owns 16,906 shares of the company’s stock worth $650,000 after buying an additional 400 shares during the last quarter. LPL Financial LLC increased its stake in Natus Medical by 4.0% in the first quarter. LPL Financial LLC now owns 13,404 shares of the company’s stock worth $399,000 after buying an additional 518 shares during the last quarter. Teacher Retirement System of Texas increased its stake in Natus Medical by 13.9% in the second quarter. Teacher Retirement System of Texas now owns 4,602 shares of the company’s stock worth $174,000 after buying an additional 562 shares during the last quarter. Finally, Envestnet Asset Management Inc. increased its stake in Natus Medical by 6.8% in the first quarter. Envestnet Asset Management Inc. now owns 9,962 shares of the company’s stock worth $383,000 after buying an additional 632 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.
Shares of Natus Medical Inc. (NASDAQ:BABY) traded up 0.63% during mid-day trading on Tuesday, hitting $43.23. The company had a trading volume of 53,347 shares. Natus Medical Inc. has a one year low of $29.54 and a one year high of $51.05. The company has a market capitalization of $1.40 billion, a PE ratio of 37.27 and a beta of 0.85. The company’s 50-day moving average is $39.67 and its 200 day moving average is $36.61.
Natus Medical (NASDAQ:BABY) last issued its quarterly earnings results on Wednesday, July 20th. The company reported $0.39 EPS for the quarter, beating the Zacks’ consensus estimate of $0.36 by $0.03. The company earned $96 million during the quarter, compared to the consensus estimate of $92.71 million. Natus Medical had a return on equity of 13.82% and a net margin of 10.20%. Natus Medical’s revenue was up 4.5% on a year-over-year basis. During the same period last year, the business posted $0.34 earnings per share. On average, equities research analysts forecast that Natus Medical Inc. will post $1.70 EPS for the current fiscal year.
A number of analysts have recently weighed in on the company. Zacks Investment Research upgraded Natus Medical from a “hold” rating to a “buy” rating and set a $44.00 target price for the company in a research report on Thursday, July 7th. Raymond James Financial Inc. upgraded Natus Medical from a “market perform” rating to an “outperform” rating and set a $46.00 price objective for the company in a research report on Tuesday, September 13th.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Want to see what other hedge funds are holding BABY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Inc. (NASDAQ:BABY).
Receive News & Ratings for Natus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.